The panel provides closing thoughts on the future of the CSCC and BCC treatment landscape.
This is a video synopsis/summary of a Peer Exchange involving Jason Luke, MD, FACP; Christopher Barker, MD; Omid Hamid, MD; Vishal Patel, MD; and Catherine Pisano, MD.
In concluding statements, Hamid reflected on tremendous progress from an era when advanced skin cancers were untreatable compared to the current landscape of effective immunotherapies and coordinated multidisciplinary care. He stressed ensuring patients understand available therapies and the ability to positively impact their disease. Pisano emphasized reclassifying basal cell and squamous cell carcinomas as serious vs indolent malignancies warranting immunotherapy when appropriate. She highlighted setting patient expectations and fully leveraging specialist expertise via integrated care teams. Barker advocated conducting pivotal trials through cooperative groups to refine care pathways, enable treatment de-escalation when feasible, and disseminate emerging strategies into community settings. Patel described the transformation of skin cancer conferences into multidisciplinary forums where cross-pollination of specialty knowledge ultimately optimizes patient-centered decision-making.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Racial Differences in CA-125 Levels Tied to Ovarian Cancer Treatment Delays
April 17th 2025Black and American Indian women with ovarian cancer were less likely to have elevated cancer antigen 125 (CA-125) levels at diagnosis, resulting in delayed chemotherapy initiation and highlighting the need for more inclusive guidelines.
Read More
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Read More